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Cytoprotection of pancreatic islets before and early after trans- and by low availability of suitable donor organs. Pancre-
plantation using gene therapy. Pancreatic islet transplantation atic islet transplantation (PIT) by intraportal vein infusion
(PIT) is an attractive alternative to insulin-dependent diabetes can circumvent surgical disadvantages of organ trans-treatment but is not yet a clinical reality. The first few days af-
plantation but clinical application of PIT has been offsetter PIT are characterized by substantial pancreatic islet dys-
by low rates of success [3–5]. The discrepancy betweenfunction and death. Apoptosis has been documented in PI
after extracellular matrix removal, during culture time, after duration of transplant function with whole pancreas or-
exposure to proinflammatory cytokines, hypoxic conditions be- gans and purified islets suggest a fundamental biologic
fore islet revascularization, and rejection. Targeting the apo- difference in these grafts.
ptosis pathway by adenoviral-mediated gene transfer of the
Although isolated PIT is susceptible to complex bio-anti-apoptotic Bcl-2 gene exerts a major cytoprotective effect
logic insults incurred during organ procurement andon isolated macaque pancreatic islets. Bcl-2 transfection ex
vivo protects islets from apoptosis induced by disruption of preservation, initial re-vascularization, proinflammatory
the islet extracellular matrix during pancreatic digestion. Ad- cytokine release, immune rejection, and the diabetogenic
ditionally, over-expression of Bcl-2 confers long-term, stable effect of immunosuppressive drugs, the isolation proce-
protection and maintenance of functional islet mass after trans-
dure itself appears to induce profound changes in isletplantation into diabetic SCID mice. Genetic modification of PI
structure and function [3, 6–10]. Tissue-specific survivalalso reduced the islet mass required to achieve stable eugly-
cemia. Ex vivo gene transfer of anti-apoptotic genes has po- factors and/or the removal of the extracellular matrix,
tential as a therapeutic approach to both minimize loss of may be responsible for eliminating cells that end up
functional islet mass post-transplant and reduce the high islet in an ectopic location (i.e., anoikis) [10–12]. The final
requirement currently needed for successful stable reversal of
outcome of these processes is destruction of the trans-insulin-dependent diabetes [1, 2].
planted islets, mainly by programmed cell death or apo-
ptosis (Fig. 1). Experimental studies have demonstrated
a significant selective decrease in the -cell mass earlyInsulin dependent diabetes mellitus (IDDM) is a dis-
after transplantation in purified canine islet autograftsorder of insulin deficiency secondary to pancreatic -cell
and in human islets transplanted into nude mice [13, 14].loss. Both the prevalence and incidence of diabetes in
Apoptosis is a highly regulated process of cell deaththe U.S. have escalated in the last 25 years. IDDM is a
and is controlled through the expression of specific geneschronic disease that may prompt a variety of complica-
that are conserved in nematodes through mammals.tions with widespread morbidity and premature mortal-
Among these, the Bcl-2 gene family is one of the mostity. IDDM is the leading cause of blindness and kidney
important [15]. The protein encoded by the Bcl-2 genefailure among adults in the U.S. IDDM is conventionally
has been implicated in the prolongation of cell survivaltreated by exogenous insulin, however, the majority of pa-
by blocking apoptosis and necrosis. Gene transfer studiestients develop one or more end-organ complications dur-
have shown that over-expression of Bcl-2 can protecting their lives. Pancreas organ transplantation, on the other
cells from death induced by a wide variety of diversehand, can permanently reverse diabetes, but success is
insults and stimuli [10, 15–25]. Given the functional im-constrained by morbidity associated with major surgery
portance of Bcl-2 gene, it constitutes a prime target for
therapeutic intervention in numerous disease states. Bcl-2
Key words: islet transplantation, gene therapy, Bcl-2 gene. is expressed in pancreatic islets and its possible that con-
tributes to the survival capacity of the islets. Over- 2002 by the International Society of Nephrology
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of PI with AdBcl-2 showed that95% of the insulin and
non-insulin producing cells over-express Bcl-2 compared
with only 10% of the cells without genetic modification
(data not shown).
After demonstration of high efficient gene transfer
in NHP islets, we sought the potential cytoprotective
properties of the Bcl-2 gene. DNA fragmentation is the
biochemical marker of apoptosis [15]. As previously re-
ported in human islets, apoptosis is a frequent event
during standard culture before transplantation [7, 9, 10,
30]. Islet cell DNA fragmentation assessed by ELISA
assay during culture time is shown in Figure 3. A signifi-
cant reduction in DNA fragmentation was observed atFig. 1. Vulnerability of pancreatic islets. Isolated pancreatic islets are
susceptible to complex biological insults incurred during pancreas pro- 7 days in culture in PI genetically modified to over-
curement and islet isolation, poor vascularization early after trans- express Bcl-2 compared with AdCMVLacZ (irrelevantplantation, exposure to proinflammatory cytokines and other immune
gene) or untransfected islets (P  0.05). These resultsmediated injuries, hyperglycemia, and the use of diabetogenic immuno-
suppressive drugs. The final outcome of these processes is destruction demonstrate the cytoprotective properties of the anti-
of the transplanted islets mainly by apoptosis. apoptotic Bcl-2 gene in NHP islets.
Initial experiments in our laboratory demonstrated
that 2000 Islet Equivalents (IEQ) NHP islets per mouse
transplanted into the portal vein is the “optimal” doseexpression of Bcl-2 in human islets and in insulinoma
for restoration of normoglycemia one day after the trans-cells prevents apoptosis induced by IL-1, IFN-, and
plant in streptozotocin (STZ)-induced SCID mice. Re-TNF- and also induces cytoprotection from hypoxia
ducing the number of unmodified islets per mouse to[20, 22].
1000 IEQ, 58% of the recipients were found euglycemicReplication-deficient adenoviral vectors are the most
on day 1 postransplant, and only 8% on day 100 (Fig. 4).efficient vectors currently available for transducing non-
Similar results were observed in recipients of islets thatdividing cells and can be produced in high titers; their
over-express an irrelevant gene (euglycemia in 50% on dayepichromosomal location diminishes the risk of inser-
1, 8% on day 100). A significant difference in the percent-tional mutagenesis. E-1 deleted adenovirus vectors have
age of euglycemic animals early and late post-transplantbeen tested in PI [26, 27]. Recently, we developed a
was observed in recipients of islets that over-expressedreplication-deficient adenoviral vector encoding the hu-
Bcl-2 (Fig. 4, P  0.005 compared with AdCMVLacZman anti-apoptotic Bcl-2 gene [16]. Gene transfer of
or unmodified islets). All recipients of a “marginal dose”
Bcl-2 induced cytoprotection of endothelial cells and
of Bcl-2 islets presented euglycemia the day after the
liver grafts during routine preservation in University of
transplant and 83% on day 100. These results demon-
Wisconsin solution for organ transplantation and after strate the ability of Bcl-2 transfected islets to reverse
reperfusion [17–19]. Over-expression of Bcl-2 decreases diabetes in STZ-induced SCID mice even after the trans-
the injury associated with an immune response generated plant of a marginal number of cells. A more sophisticated
by adenoviral vectors after in vivo gene transfer to the form of metabolic evaluation of the transplanted islets
liver [16, 28]. In our laboratory, we evaluated the poten- is demonstrated in Figure 5. The glucose disposal rate
tial of genetic modification of nonhuman primate (NHP) (Kg), a measure of functional islet mass, became progres-
pancreatic islets by gene transfer of Bcl-2 as an approach sively reduced over time, indicating loss of islet mass
to prevent loss of pancreatic -cells before and early [31, 32]. By 30 days after the transplant, glucose disposal
after transplantation. rate was reduced to pre-transplant diabetic values in the
Numerous publications have demonstrated that adeno- two control groups (unmodified islets or islets trans-
viruses are very efficient at infecting human and rodent fected with LacZ). In contrast, no significant change in
islets ex vivo [26, 27, 29]. However, no experience in gene the capacity to dispose glucose was observed in animals
transfer in nonhuman primate islets has been reported. that received islets transduced with Bcl-2.
Initial experiments in our laboratory demonstrated that One of the current limitations in clinical islet trans-
95% of the cells in non-human primate islets expressed plantation is the availability of cadaver organs [2, 3, 5].
the transgene after genetic modification with adenoviral After demonstration of the cytoprotective effects of
vectors at 500 pfu/cell (Fig. 2A, B, C, and D). Bcl-2 Bcl-2, next we sought the islet mass required to establish
expression after gene transfer with an adenoviral vector stable euglycemia after transplantation. Most of the dia-
(AdBcl-2) was confirmed by Western blot (Fig. 2E). An betic recipients that received 2000 IEQ were found eu-
glycemic 3 and 15 days post-transplantation. Reducingimmunohistochemical analysis after genetic modification
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Fig. 2. Transfection efficiency of adenoviral vectors in non-human primate pancreatic islets. NHP islets were infected ex vivo with different
concentrations of an E1-deleted adenoviral vector encoding -galactosidase (A  none, B  10 pfu/cell, C  100 pfu/cell, and D 500  pfu/cell).
An immunohistochemical analysis demonstrated that more than 95% of the cells expressed the reporter gene (LacZ). Bcl-2 expression after gene
transfer with similar E1-deleted adenoviral vector encoding the human Bcl-2 gene was confirmed by Western blot (E). Immunoblot analysis was
performed as described in Methods. Lane 1: positive control; Lane 2: NHP islets transfected with an adenovirus vector encoding an irrelevant
gene (LacZ); Lane 3: NHP islets transfected with AdCMVhBcl-2.
with AdCMVBcl-2. Similar results were observed at 15
days post-transplant These results have a significant clini-
cal implication because gene transfer of Bcl-2 potentially
will reduce the number of cells per recipient required to
achieve euglycemia without exogenous insulin adminis-
tration.
In summary, targeting the apoptosis pathway with gene
transfer of Bcl-2 is an attractive cytoprotective alternative
in pancreatic islets during culture time and early after
transplantation. Gene transfer of anti-apoptotic genes is
a potential new therapeutic approach for successful islet
transplantation.
Fig. 3. Bcl-2 transfected islets analysis for spontaneous apoptosis dur-
ing culture by ELISA. NHP islets were incubated without virus (mock),
AdCMVLacZ, or AdCMVhBcl-2 and cultured as described in Methods. METHODS
DNA fragmentation was assessed at 7 days. Data are mean  SE for
Animalsislets from 3 different isolations and are expressed as enrichment factors,
which represent the ratio of optical densities for control and experimen- Normal, 4–6 kg male rhesus monkeys (Maccaca mu-tal conditions. *P  0.05 vs. AdCMVLacZ and vs. Mock.
latta) were obtained from breeding colonies at LABS
(Yamassee, SC), University of Wisconsin (Madison, WI),
and Hazelton (Alice, TX). Male SCID mice (Jackson
the number of islets to 1000 IEQ, 55–58% of the animals Laboratory, Bar Harbor, ME), 9 to 12 weeks old (25–30 g),
that received unmodified islets or islets transfected with were fed on a laboratory diet with water and food ad
LacZ were euglycemic compared with 100% of the ani- libitum. Surgical and nonsurgical procedures were car-
mals that received islets transfected with Bcl-2. With 500 ried out in accordance the National Institutes of Health
IEQ, none of the animals that received unmodified islets Guide for the Care and Use of Primates under supervi-
or islets treated with AdCMVLacZ were euglycemic com- sion of the Institutional Animal Care and Use Commit-
tee. SCID mice were made diabetic by a single intraperi-pared with 100% of the animals that received islets treated
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Fig. 4. Stable reversal of blood glucose in streptozotocin induced diabetic SCID mice after transplantation of Bcl-2 transfected NHP islets. Animals
received a suboptimal dose of 1000 IEQ/mouse into the portal vein (N  12 per group). NHP islets were not exposed to virus (Mock) or transfected
with AdCMVLacZ or AdCMVhBcl-2. Tail vein blood glucose was determined as described in Methods.
tate Liberase-HI (Boehringer-Mannheim, Indianapolis,
IN) digestion. The islets were separated by the semiauto-
mated technique and purified using a COBE-2991 Cell
processor (COBE, Lakewood, CO). The time between
pancreas procurement and islet isolation was routinely
 2 hours. The isolated islets were incubated in supple-
mented CMRL 1066 (Mediatech) and 10% heat-inacti-
vated fetal calf serum (FCS) at 26C with 5% CO2 for
12 hours before the gene transfer. Islet Equivalent num-
ber was assessed after dithizone staining and counting
under the inverted microscope as described. The viability
was determined by staining with ethidium bromide and
acridine orange, then determined by two-color fluores-
cence microscopy. The routine number of IEQ/pancreas
was 112,066  46,149 IEQ/donor. Only preparations
with viability and purity90% were used. All the experi-
ments were performed on the islets derived from a single
donor in triplicate and repeated on at least four occasions
from subsequent donors.Fig. 5. Recipients of Bcl-2 transfected NHP islets presented stable islet
mass after transplantation. Glucose disposal rate after an intraperitoneal
glucose tolerance test was performed as described in methods on day Generation of a recombinant adenovirus vector and
–2 (before the transplant), 3, 10, 15, and 30 after intraportal transplanta- gene transfertion of 1000 IEQ/mouse. NHP islets were not transfected (mock or
transfected with AdCMVLacZ or AdCMVhBcl-2). Tail vein blood glu- A recombinant, E1 deleted adenovirus carrying the
cose was determined after a glucose challenge as described in Methods.
human Bcl-2 gene under the control of the cytomegalo-Data are means  SE for 6 animals from 3 different islet preparations.
virus promoter (AdCMVhBcl-2) was constructed as
previously described [16]. A similar recombinant adeno-
virus encoding the reporter gene E coli 	galactosidasetoneal injection of freshly reconstituted 200 mg/kg of
(AdCMVLacZ) was used as a control. A plaque assaystreptozotocin (Sigma). Recipient blood glucose levels
on HeLa cells confirmed the absence of spontaneouslywere monitored by glucose oxidase strips using a Boeh-
generated replication competent adenovirus. Pancreaticringer-Mannheim Accu Check III (blood obtained from
islets were washed twice in CMRL 1066, supplementedthe tail vein). Diabetes was defined as blood glucose levels
as described previously with 2% of FCS. 1000 or 2000300 mg/dL for 3 consecutive days. Normoglycemia was
IEQ were infected in 24-well tissue plates at 500 par-defined as non-fasting blood glucose 200 mg/dL.
ticle forming units/cell in a minimum volume of 0.5 mL
Islet isolation at 37C. After 2 hours, CMRL 1066 supplemented as
previously with 10% FCS was added and cultured over-Pancreata were procured from normal monkeys as de-
scribed [33]. The pancreatic duct was cannulated to facili- night at 26C and 5% CO2. After the infection, the islets
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